Allspring Global Investments Holdings LLC Purchases 50,888 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Allspring Global Investments Holdings LLC grew its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 13.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 417,332 shares of the biopharmaceutical company's stock after purchasing an additional 50,888 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.35% of Catalyst Pharmaceuticals worth $8,710,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in CPRX. SG Americas Securities LLC bought a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at about $173,000. CWM LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 128.7% in the third quarter. CWM LLC now owns 9,298 shares of the biopharmaceutical company's stock worth $185,000 after buying an additional 5,232 shares during the period. Creative Planning boosted its holdings in shares of Catalyst Pharmaceuticals by 26.9% in the third quarter. Creative Planning now owns 12,724 shares of the biopharmaceutical company's stock worth $253,000 after buying an additional 2,699 shares during the period. nVerses Capital LLC acquired a new position in shares of Catalyst Pharmaceuticals in the third quarter worth about $50,000. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 11.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 20,017 shares of the biopharmaceutical company's stock worth $398,000 after buying an additional 1,989 shares during the period. Institutional investors own 79.22% of the company's stock.

Insider Activity at Catalyst Pharmaceuticals

In related news, Director Molly Harper sold 17,500 shares of the firm's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Steve Miller sold 50,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares in the company, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 79,500 shares of company stock valued at $1,754,140. 11.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several recent analyst reports. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Bank of America reiterated a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. StockNews.com cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, January 11th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an "overweight" rating and a $35.00 target price for the company. Finally, HC Wainwright raised their target price on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Friday, January 10th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $32.25.

Catalyst Pharmaceuticals Price Performance

CPRX traded down $0.42 during midday trading on Friday, hitting $21.63. 918,442 shares of the company's stock traded hands, compared to its average volume of 1,235,671. The company has a market cap of $2.58 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 3.38 and a beta of 0.80. The stock's fifty day simple moving average is $22.25 and its 200-day simple moving average is $21.25. Catalyst Pharmaceuticals, Inc. has a one year low of $13.49 and a one year high of $24.64.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.